Multi-Pathogen Vaccine Kit
Prevention of multiple infections (SARS-CoV-2, Influenza, HPV, etc.)
Pre-clinical/DevelopmentActive
Key Facts
Indication
Prevention of multiple infections (SARS-CoV-2, Influenza, HPV, etc.)
Phase
Pre-clinical/Development
Status
Active
Company
About AIVITA Biomedical
AIVITA Biomedical is a private, clinical-stage biotech leveraging its proprietary stem cell and autologous immunotherapy platform to develop personalized vaccines. Its lead oncology programs target glioblastoma and melanoma, with a Phase 2/3 trial planned for glioblastoma and a Phase 1B trial ongoing in melanoma. The company has also developed a multi-pathogen vaccine kit and funds its R&D in part through a clinically validated skincare product line.
View full company profile